Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor

Table 3

Therapy following ASCT and outcomes.

Pt#	Time to radiotherapy after ASCT (weeks)	Treatment at relapse	OS (months) after ASCT	EFS (months); after ASCT
First complete remission before ASCT
1	No radiotherapy	None	5.3	1.4
2	12	N/A	239.1	239.1
3	10	Irinotecan/temozolomide; cyclophosphamide/vinorelbine; sunitinib; bevacizumab	48.4	13.7
4	15	Oral etoposide	30.1	13.2
5	12	Unknown	51.1	21.4
6	12	None	26.7	16.5
7	12	N/A	196.0	196.0
8	No radiotherapy	Paclitaxel, thiotepa	14.3	8.4
Persistent but chemosensitive disease before ASCT
9	21	Vincristine, cyclophosphamide, dactinomycin	15.3	5.2
10	11	Palliative radiotherapy; oral etoposide	18.7	12.4
11	13	None	12.0	9.7
12	6	Exatecan	39.5	19.1
13	11	N/A	18.6	8.2 (developed secondary AML)
14	13	Temozolomide	23.8	16.4
15	13	Irinotecan, cisplatin; thalidomide; palliative radiotherapy	80.5	25.3
16	34	Vinorelbine	9.6	3.1
Relapse before ASCT
17	12	N/A	39.7	12.1 (developed secondary AML)
18	12	Oral etoposide, vinorelbine, cisplatin, topotecan	23.2	8.7
19	14	None	10.1	7.1

AML: Acute myeloid leukemia; ASCT: autologous stem cell transplant; EFS: event-free survival; N/A: not applicable; OS: overall survival.